Elesta announces that the Chinese regulatory authority National Medical Products Administration (NMPA) has approved EchoLaser for use in prostatic diseases. This approval is a major achievement and represents a great opportunity for Elesta (distributed in China by...
The theoretical – practical course at the LXY Institute in Madrid, where EchoLaser TPLA played a central role as a treatment for IPB, ended. Discover more thanks to Dr. Pablo Garrido Abad! III Edición Curso Práctico en STUI y Patología Vesicoprostática basado en...
At Elesta, we are committed to improving men’s health and that’s why we are proud to be part of the Movember movement this November. Together with EchoLaser TPLATM, we’re taking a stand for a cause that matters. 🌟 *Our Mission:* Elesta is dedicated...
We are happy to say that #EchoLaser #SoracteLite #TPLA has been recognized as one of the most crucial updates for #EAU23. A safe way to treat #BPH that preserves sexual function....
EAU2023 has come to an end. Scientific sessions demonstrated the constant and solid progress EchoLaser is making as a game changer for the treatment of BPH: The first randomized clinical trial vs TURP shows that 96% of the patients treated with EchoLaser were able to...
This site uses cookies to provide you with a better browsing experience. By accepting this banner, scrolling down this page, clicking on a link or continuing to browse in any other way, you consent to the use of cookies. If want to know more read our cookie policy. AcceptRead the policy
